Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
Completed · Phase 2
Conditions studied: Hepatitis C, Hepatitis
In brief
This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously responded to this therapy. Approximately 315 subjects will be enrolled in this research study at approximately 55 clinical sites in the United States. There will be three study groups. Everyone in the study will receive Pegasys® (pegylated interferon) and Copegus® (ribavirin) at the normally prescribed doses. Two of the groups will also receive the study drug merimepodib (MMPD) twice a day, one group at each dose level being tested. The third group will take a placebo instead of MMPD, with the Pegasys® and Copegus®. After the first 24 weeks of treatment, blood tests will be done to see if subjects are responding to treatment. If they are responding, they will continue receiving study treatment in the study for another 24 weeks. If they are not responding, they will stop study treatment. Everyone who is responding will be monitored for 24 weeks after the last dose of medication, to see how long the response lasts. Evaluations will be performed during the study to look at the safety of the Pegasys®/Copegus® and MMPD or placebo combination, and to see how the combination is working by measuring Hepatitis C Virus in the blood. At some of the clinical sites performing the study, some subjects may also participate in additional testing to look at the metabolism of the drugs, or to look at the immune response to Hepatitis C virus infection and treatment.
Key facts
- Study ID
- NCT00088504
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 315
- Starts
- 2004-07-01
- Expected to finish
- 2006-10-01
- Last updated by the study team
- 2007-12-21
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The following is a summary of the inclusion and exclusion criteria for the Merimepodib Triple Combination (METRO) trial. There are also additional criteria, which will be reviewed with you by the staff at the clinical study site, to make sure you are eligible for the study. Some of the criteria are dependent on the results of blood tests and other tests that will be done at the clinical site.
- If you are not sure whether you meet these criteria, please call the clinical study site nearest you, and they can help you figure out if you might be eligible for the study:
- You must have been diagnosed with Hepatitis C.
- You must have been treated with pegylated interferon (brand names are Pegasys® or Peg-Intron®) and ribavirin (brand names Rebetol® or Copegus®), for at least 12 weeks. However, you cannot have received more than one course of this combination therapy.
- You must have been a "non-responder" to this treatment, meaning that the virus levels in your blood were always detectable. If you responded to the treatment and then the virus became detectable again (called a "relapse"), you would not be eligible.
- You must not have used illegal drugs, or have a history of significant alcohol use, within the last year before you start the study.
- Pegasys® and Copegus® are not recommended for people with some illnesses. You should be in good health in general, with no illnesses that would prevent you from using Pegasys® and Copegus®. If you do not know whether you have any illness or conditions that would prevent you from using these medications, the study doctor or nurse will review your medical history with you to determine this.
- If you are a woman who can have children, you must be willing to use two effective methods of birth control during the study and for 6 months after the last dose of the medication. You will have monthly pregnancy tests during this time to make sure you do not become pregnant (This is recommended for anyone taking ribavirin, even when they are not in a clinical study.).
- If you are a male, your female partner must not be pregnant, and you both must be willing to use birth control during the time you are in the study, and for 6 months after the last dose of the medication (This is recommended for anyone taking ribavirin, even when they are not in a clinical study.).
Where it is running
- Suresh Karne, M.D., Ph.D. — Huntsville, Alabama, United States
- Vijayan Balan, M.D. — Phoenix, Arizona, United States
- Michael P. DeMicco, M.D. — Anaheim, California, United States
- Prahalad B. Jajodia, M.D. — Fresno, California, United States
- F. Fred Poordad, M.D. — Los Angeles, California, United States
- Ramsey Cheung, M.D. — Palo Alto, California, United States
- Myron J. Tong, M.D., Ph.D. — Pasadena, California, United States
- Michael T. Bennett, M.D. — San Diego, California, United States
- Lisa M. Nyberg, M.D. — San Diego, California, United States
- Natalie Bzowej, M.D. — San Francisco, California, United States
- Marcelo Kugelmas, M.D. — Englewood, Colorado, United States
- Herbert L. Bonkovsky, M.D. — Farmington, Connecticut, United States
- Eugene R. Schiff, M.D. — Miami, Florida, United States
- Jawahar L. Taunk, M.D. — Palm Harbor, Florida, United States
- Arnold L. Lentnek, M.D. — Marietta, Georgia, United States
- Ellen B. Hunter, M.D. — Boise, Idaho, United States
- Steven L. Flamm, M.D. — Chicago, Illinois, United States
- Helen Te, M.D. — Chicago, Illinois, United States
- Gerald J. Mingoletti, M.D. — Oak Forest, Illinois, United States
- Donald R. Graham, M.D. — Springfield, Illinois, United States
- Alvaro G. Koch, M.D. — Lexington, Kentucky, United States
- Shaban Faruqui, M.D. — Baton Rouge, Louisiana, United States
- Robert M. Be, M.D. — Baton Rouge, Louisiana, United States
- Bal Raj Bhandari, M.D. — Monroe, Louisiana, United States
- Joseph L. Cochran, M.D. — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.